Pidnarulex Clinical Trials
4 recruitingDrug
Phase 14Phase 22
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Burkitt LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDouble-Expressor Lymphoma
National Cancer Institute (NCI)50 enrolled4 locationsNCT07069699
Recruiting
Phase 1Phase 2
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Stage IV Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma+2 more
National Cancer Institute (NCI)86 enrolled1 locationNCT07147231
Recruiting
Phase 1
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled1 locationNCT07137416
Recruiting
Phase 1
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
Metastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)40 enrolled1 locationNCT06606990